Improving intermittent androgen deprivation therapy: lessons learned from basic and translational research.

Area of Science:

• Oncology
• Urology
• Pharmacology

Background:

• Continuous androgen deprivation therapy (ADT) for prostate cancer causes significant side effects.
• Intermittent androgen deprivation therapy (IADT) was developed to improve quality of life and delay castration resistance.
• IADT demonstrates comparable efficacy to ADT for biochemical recurrence but has inconclusive results in metastatic disease.

Purpose of the Study:

• To review the survival benefits of 5 alpha-reductase inhibition during IADT off-cycles in animal models.
• To explore the potential clinical translation of this therapeutic strategy.

Main Methods:

• Review of existing clinical trials comparing IADT and ADT.
• Analysis of recent studies investigating 5 alpha-reductase inhibitors in combination with IADT in murine models of prostate cancer.

Main Results:

• IADT offers slightly improved quality of life compared to ADT.
• IADT is noninferior to ADT for biochemical recurrence.
• Preliminary animal studies indicate that 5 alpha-reductase inhibitors during IADT off-cycles can significantly prolong survival in androgen-sensitive prostate tumors.

Conclusions:

• 5 alpha-reductase inhibition during IADT off-cycles presents a potential strategy to enhance survival in prostate cancer.
• Further clinical investigation is warranted to validate these findings in human patients.